News

MSAA, Lumina partner to provide MRIs to MS patients in Ohio

Lumina Imaging has partnered with the Multiple Sclerosis Association of America (MSAA) to provide affordable brain and spinal cord MRI scans to multiple sclerosis (MS) patients. The partnership makes Lumina the preferred provider for the MSAA’s MRI Access Program in northeast Ohio. The program is designed…

New bilingual graphic aims to raise awareness of early MS symptoms

A bilingual graphic educational message, dubbed VISIBL-MS, has been developed by researchers at the University of Connecticut (UConn) to raise awareness about the early symptoms of multiple sclerosisĀ (MS). The graphic ā€” bearing the word ā€œVISIBLYā€ in English and ā€œVISIBLEā€ in Spanish ā€” uses the letters in each phrase…

Metabolon, Cardiff University partner for MS biomarker research

Metabolon and Cardiff University are partnering to discover new biomarkers that could help better understand disease mechanisms and develop new treatments for multiple sclerosis (MS). The project leverages Metabolon’s expertise in metabolomics, a field of research that measures all products of metabolism, called metabolites, that are made…

Rituximab for MS may safely control disease in children, teens

Treatment with rituximab, an approved CD20 inhibitor that’s sometimes used off-label for multiple sclerosis (MS), was found to adequately control the neurodegenerative disease in patients diagnosed during childhood or adolescence, a new study showed. The therapy, given byĀ  infusion into the bloodstream, was generally safe and significantly reduced…

Exercise improves mental health, life quality for MS patients: Analysis

Getting physical exercise can improve subjective well-being and health-related quality of life for people with multiple sclerosis (MS), a new meta-analysis shows. “Exercise interventions, especially aerobic or combined aerobic and resistance training, should be implemented in clinical practice to promote mental health” and health-related quality of life in people…

Phase 1 trial of KYV-101 opening in progressive MS without relapses

Researchers at Stanford University have partnered with Kyverna Therapeutics to conduct an investigator-initiated clinical trial of the company’s cell-based therapy, KYV-101, in people with progressive forms of multiple sclerosis (MS) without relapses. The open-label Phase 1 trial (NCT06138132) will take place at the Stanford Multiple Sclerosis…

Common MS therapies appear safe to use while breastfeeding

Taking antibody-based medications for multiple sclerosis (MS) while breastfeeding does not appear to harm a child’s health or development during at least the first three years of life, according to a preliminary study of more than 180 babies. Children breastfed by mothers taking Tysabri (natalizumab), Ocrevus (ocrelizumab),…

Briumvi, an infusion treatment for MS, granted 3 more patents

TG Therapeutics has secured three additional U.S. patents for Briumvi (ublituximab-xiiy), an anti-CD20 antibody that’s been approved to treat relapsing forms of multiple sclerosis (MS). Issued by the U.S. Patent and Trademark Office, the patent numbers 11,807,689; 11,814,439; and 11,884,740 specifically cover the composition and…

ACTRIMS 2024: Progressive MS patients show gains in NG-01 OLE

Repeated treatment with the mesenchymal stem cell therapy NG-01 led to gains in mobility and cognition, along with patient-reported quality of life, for most people with progressive multiple sclerosis (MS) in an extension study. Markers of nerve damage were also reduced, indicating significant nerve-protecting effects. Dimitrios Karussis, MD,…

ACTRIMS 2024: Molecule made by gut bacteria seen to ease MS in mice

Supplements of indole 3-lactate (ILA), a molecule made by gut bacteria, significantly reduced disease severity and promoted myelin repair in mouse models of multiple sclerosis (MS). That’s according to new findings presented by Larissa Jank, PhD, a postdoctoral researcher at Johns Hopkins University, at the Americas Committee for Treatment…

Briumvi for relapsing MS now available for patients in Europe

Briumvi (ublituximab-xiiy), an approved treatment for relapsing forms of multiple sclerosis (MS), is now available to patients in Europe, where itā€™s being marketed by Neuraxpharm. The infusion therapy, developed by TG Therapeutics, was first launched in Germany, with additional rollouts following in other European countries. Under…